Topics

Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval

16:22 EST 8 Nov 2019 | Xconomy

A drug that Celgene and Acceleron Pharma developed to treat low red blood cell levels in patients who have a rare blood disorder now has regulatory clearance to enter the market. The FDA on Friday approved luspatercept (Rebloyzl) for patients who have beta thalassemia, an inherited disorder that leads to anemia, or low levels of […]

Original Article: Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval

NEXT ARTICLE

More From BioPortfolio on "Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval"

Quick Search

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...